Omnicell is trading at $38.33, up 6.62%, after strong third-quarter results and raised full-year EPS guidance.
- Adjusted EPS was $0.58 versus the $0.42 analyst estimate; revenue of $307.85 million also topped estimates.
- Full-year 2026 adjusted EPS outlook rose to $2.48–$2.56, compared with analyst consensus of $2.27, after strong quarterly profitability.
- Fourth-quarter revenue guidance was below consensus. Trading volume and activity data were unavailable in the provided price context.